Analytical Method Development and Validation for HPLC-ECD Determination of Moxifloxacin in Marketed Formulations

G. Phani Sekhar Reddy; K. S. Navyasree; P. C. Jagadish; Krishnamurthy Bhat

doi:10.1007/s11094-018-1879-1

Analytical Method Development and Validation for HPLC-ECD Determination of Moxifloxacin in Marketed Formulations

G. Phani Sekhar Reddy
, K. S. Navyasree
, P. C. Jagadish
, Krishnamurthy Bhat^*

^*Corresponding author for this work

Department of Pharmaceutical Quality Assurance, Manipal College of Pharmaceutical Sciences, Manipal

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

An HPLC-ECD analytical method with high reproducibility and wide linearity range has been developed and validated. Moxifloxacin was separated and identified using this method with a simple mobile phase comprising Britton Robinson buffer pH 5.0 and methanol (93: 7 v/v) flowing at a rate of 0.5 mL/min through Acclaim C₁₈ column (150 mm × 4.6 mm × 5 im) maintained at 35°C and detected at redox potential value of 1.0 V. The LOD and LOQ were found to be 2.2 and 6.6 μg/mL, respectively. The HPLC-ECD method of moxifloxacin analysis was validated as per ICH Q₂R₁ guidelines and applied for assay of marketed moxifloxacin formulations to establish the acceptable recovery.

Original language	English
Pages (from-to)	674-679
Number of pages	6
Journal	Pharmaceutical Chemistry Journal
Volume	52
Issue number	7
DOIs	https://doi.org/10.1007/s11094-018-1879-1
Publication status	Published - 01-10-2018

All Science Journal Classification (ASJC) codes

Pharmacology
Drug Discovery

Access to Document

10.1007/s11094-018-1879-1

Cite this

@article{5409089896844071818b9f23d308b8c7,

title = "Analytical Method Development and Validation for HPLC-ECD Determination of Moxifloxacin in Marketed Formulations",

abstract = "An HPLC-ECD analytical method with high reproducibility and wide linearity range has been developed and validated. Moxifloxacin was separated and identified using this method with a simple mobile phase comprising Britton Robinson buffer pH 5.0 and methanol (93: 7 v/v) flowing at a rate of 0.5 mL/min through Acclaim C18 column (150 mm × 4.6 mm × 5 im) maintained at 35°C and detected at redox potential value of 1.0 V. The LOD and LOQ were found to be 2.2 and 6.6 μg/mL, respectively. The HPLC-ECD method of moxifloxacin analysis was validated as per ICH Q2R1 guidelines and applied for assay of marketed moxifloxacin formulations to establish the acceptable recovery.",

author = "\{Phani Sekhar Reddy\}, G. and Navyasree, \{K. S.\} and Jagadish, \{P. C.\} and Krishnamurthy Bhat",

note = "Publisher Copyright: {\textcopyright} 2018, Springer Science+Business Media, LLC, part of Springer Nature.",

year = "2018",

month = oct,

day = "1",

doi = "10.1007/s11094-018-1879-1",

language = "English",

volume = "52",

pages = "674--679",

journal = "Pharmaceutical Chemistry Journal",

issn = "0091-150X",

publisher = "Springer New York",

number = "7",

}

TY - JOUR

T1 - Analytical Method Development and Validation for HPLC-ECD Determination of Moxifloxacin in Marketed Formulations

AU - Phani Sekhar Reddy, G.

AU - Navyasree, K. S.

AU - Jagadish, P. C.

AU - Bhat, Krishnamurthy

PY - 2018/10/1

Y1 - 2018/10/1

N2 - An HPLC-ECD analytical method with high reproducibility and wide linearity range has been developed and validated. Moxifloxacin was separated and identified using this method with a simple mobile phase comprising Britton Robinson buffer pH 5.0 and methanol (93: 7 v/v) flowing at a rate of 0.5 mL/min through Acclaim C18 column (150 mm × 4.6 mm × 5 im) maintained at 35°C and detected at redox potential value of 1.0 V. The LOD and LOQ were found to be 2.2 and 6.6 μg/mL, respectively. The HPLC-ECD method of moxifloxacin analysis was validated as per ICH Q2R1 guidelines and applied for assay of marketed moxifloxacin formulations to establish the acceptable recovery.

AB - An HPLC-ECD analytical method with high reproducibility and wide linearity range has been developed and validated. Moxifloxacin was separated and identified using this method with a simple mobile phase comprising Britton Robinson buffer pH 5.0 and methanol (93: 7 v/v) flowing at a rate of 0.5 mL/min through Acclaim C18 column (150 mm × 4.6 mm × 5 im) maintained at 35°C and detected at redox potential value of 1.0 V. The LOD and LOQ were found to be 2.2 and 6.6 μg/mL, respectively. The HPLC-ECD method of moxifloxacin analysis was validated as per ICH Q2R1 guidelines and applied for assay of marketed moxifloxacin formulations to establish the acceptable recovery.

UR - https://www.scopus.com/pages/publications/85056115110

UR - https://www.scopus.com/pages/publications/85056115110#tab=citedBy

U2 - 10.1007/s11094-018-1879-1

DO - 10.1007/s11094-018-1879-1

M3 - Article

AN - SCOPUS:85056115110

SN - 0091-150X

VL - 52

SP - 674

EP - 679

JO - Pharmaceutical Chemistry Journal

JF - Pharmaceutical Chemistry Journal

IS - 7

ER -

Analytical Method Development and Validation for HPLC-ECD Determination of Moxifloxacin in Marketed Formulations

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this